<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02514070</url>
  </required_header>
  <id_info>
    <org_study_id>150173</org_study_id>
    <secondary_id>15-H-0173</secondary_id>
    <nct_id>NCT02514070</nct_id>
  </id_info>
  <brief_title>Comparison of EPA and DHA-Rich Fish Oils on Lipoprotein Metabolism In Adults</brief_title>
  <official_title>Comparison of EPA and DHA-Rich Fish Oils on Lipoprotein Metabolism In Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      - Metabolism is what the body does to turn food into energy. Omega-3 fatty acids are&#xD;
      substances found in foods such as cold-water fish and shellfish that are essential for good&#xD;
      health. Researchers want to see the effect of two fatty acids eicosapentaenoic acid (EPA) and&#xD;
      docosahexaenoic acid (DHA) on metabolism. They may be beneficial to cardiovascular health.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      - To understand the effects of EPA and DHA on metabolism.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      - Healthy people ages 18 years or above with plasma triglyceride (a type of fat in the blood)&#xD;
      levels of 100 mg/dL or higher&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  The study will last 20 to 24 weeks.&#xD;
&#xD;
        -  Participants will have 4 visits to the NIH Clinical Center. These will include:&#xD;
&#xD;
        -  Medical history&#xD;
&#xD;
        -  Physical Fasting blood and urine tests&#xD;
&#xD;
        -  CAVI tests: blood pressure is taken in the arms and legs, and the heart is monitored.&#xD;
&#xD;
        -  Participants will take an EPA/DHA dietary supplement. They will take 4 gel capsules, 3&#xD;
           times a day, for 6 or 7 weeks. Then they will not take the capsules for 8 to 10 weeks (a&#xD;
           wash-out period). They will then take the capsules again for 6 or 7 weeks.&#xD;
&#xD;
        -  Participants will keep a food journal.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a novel randomized crossover, double-blinded pilot study that aims to investigate the&#xD;
      effects of different omega-3 fatty acids, namely EPA and DHA, on lipoprotein metabolism.&#xD;
      Subjects will be unblinded for performance of measurements after they complete the study.&#xD;
      Subjects will receive EPA or DHA supplements for approximately 6 weeks with a wash out period&#xD;
      of 8 weeks between the two arms of the study. The study consists of 4 outpatient visits when&#xD;
      laboratory or research samples and CAVI tests will be performed. A 7-day food diary, pill&#xD;
      count, and red cell membrane n-3 levels will be monitored to assess compliance.&#xD;
&#xD;
      Serum cholesterol is transported by lipoproteins, such as VLDL, LDL and HDL, which vary in&#xD;
      their relationship to cardiovascular risk. LDL is proatherogenic, whereas HDL is&#xD;
      cardio-protective. Fish oil supplementation, such as EPA and DHA, has been shown to reduce&#xD;
      triglycerides. EPA supplementation has also been shown to lower LDL-C, whereas DHA can raise&#xD;
      both LDL-C and HDL-C. These differential effects on lipoproteins may alter the cardiovascular&#xD;
      protection afforded by fish oil supplementation. This study will test the hypothesis that EPA&#xD;
      and DHA may differ in their LDL-C lowering ability because of differences in how they&#xD;
      modulate plasma PCSK9 levels, which is a major determinant of LDL-C levels. In addition, we&#xD;
      will assess other parameters related to lipoprotein composition and function that may impact&#xD;
      the cardioprotective effect of EPA and DHA. Other reported beneficial effects of omega-3&#xD;
      fatty acid supplementation, such as decreased platelet coagulability, markers of inflammation&#xD;
      and changes in guy microbiota, will also be monitored.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2015</start_date>
  <completion_date type="Actual">July 23, 2019</completion_date>
  <primary_completion_date type="Actual">July 23, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma PCSK9 Levels at Baseline and End of 6 Week Intervention</measure>
    <time_frame>baseline to 6 weeks of intervention</time_frame>
    <description>Measure plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) level, at baseline, after 6 weeks of Eicosapentaenoic acid (EPA) or Docosahexaenoic acid (DHA) fish oil supplementation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Levels in Triglyceride, Cholesterol, and Lipoprotein From Baseline to 6 Weeks</measure>
    <time_frame>Baseline to 6 weeks of intervention</time_frame>
    <description>Measure plasma levels at baseline to 6 weeks of intervention for the following: triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), lipoprotein particle composition and size, and high-density lipoprotein (HDL) cholesterol efflux capacity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Lipoprotein Metabolism</condition>
  <condition>PCSK9</condition>
  <condition>Proteomics</condition>
  <arm_group>
    <arm_group_label>EPA-rich fish oil arm then DHA-rich fish oil arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to the EPA-rich fish oil arm will take the equivalent to 3g of EPA /day (12 gel capsules/day) for 6 more or less 1 weeks and cross-over to the DHA-rich capsule arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DHA-rich fish oil arm then EPA-rich fish oil arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to the DHA-rich fish oil arm will take the equivalent to 3g of DHA /day (12 gel capsules/day) for 6 more or less 1 weeks and cross-over to the EPA-rich capsule arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPA-rich fish oil</intervention_name>
    <description>4 gel capsules, 3 times/day for 6 weeks</description>
    <arm_group_label>EPA-rich fish oil arm then DHA-rich fish oil arm</arm_group_label>
    <other_name>Eicosapentaenoic acid (EPA) Fish Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHA-rich fish oil</intervention_name>
    <description>4 gel capsules, 3 times/day for 6 weeks</description>
    <arm_group_label>DHA-rich fish oil arm then EPA-rich fish oil arm</arm_group_label>
    <other_name>Docosahexaenoic acid (DHA) Fish Oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  Male and female participants 18 years of age or above.&#xD;
&#xD;
          -  Subject must be healthy, with no known history of cardiovascular disease.&#xD;
&#xD;
          -  Subject understands protocol and provides written, informed consent in addition to a&#xD;
             willingness to comply with specified follow-up evaluations.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Pregnancy, planned pregnancy (within the study period) or women currently&#xD;
             breastfeeding.&#xD;
&#xD;
          -  Subjects with weight changes greater than 20% over the past 3 months.&#xD;
&#xD;
          -  Subjects planning a significant change in diet or exercise levels.&#xD;
&#xD;
          -  Subjects already consuming more than 1.5 g per day of Eicosapentaenoic Acid (EPA) or&#xD;
             Docosahexaenoic Acid (DHA) in any form.&#xD;
&#xD;
          -  Subjects taking supplements or medications that affect lipoproteins for at least the&#xD;
             past six weeks including fish oil supplements, bile-acid sequestrants, plant sterol&#xD;
             supplements, fibrates, statins or Niacin.&#xD;
&#xD;
          -  Subjects diagnosed with cancer or IBD, or that have taken diarrhea inhibitors,&#xD;
             laxatives or prebiotics in the week before stool sampling (optional), or antibiotics&#xD;
             within 3 months before sampling.&#xD;
&#xD;
          -  Subjects taking daily aspirin or other anti-platelet or anti-coagulants agents&#xD;
             (Plavix).&#xD;
&#xD;
          -  History of prostate Cancer&#xD;
&#xD;
          -  Subjects with known bleeding disorders (for example, Hemophilia)&#xD;
&#xD;
          -  Known sensitivity or allergy to fish, shellfish or omega-3 fatty acids supplements&#xD;
&#xD;
          -  Subjects with chronic diarrhea, gastric bypass or lap-band procedures, ostomies, bowel&#xD;
             motility problems, or other conditions that could affect intestinal fat absorption&#xD;
&#xD;
          -  Subjects with any acute and life-threatening condition, such as prior sudden cardiac&#xD;
             arrest, acute myocardial infarction (last three months), stroke, embolism&#xD;
&#xD;
          -  Liver enzymes (aspartate aminotransferase (AST) or alanine transaminase (ALT)) levels&#xD;
             above 3x upper limit of normal&#xD;
&#xD;
          -  Subjects initiating new medications or patients on multiple medications may also be&#xD;
             excluded according to investigator discretion&#xD;
&#xD;
          -  Subjects previously diagnosed with cardiac dysrhythmia&#xD;
&#xD;
          -  Subjects with clinically diagnosed hepatic disease (including but not limited to auto&#xD;
             immune disease, hepatitis and cirrhosis)&#xD;
&#xD;
          -  Anticipated surgery during the study period&#xD;
&#xD;
          -  Blood donation in the last 2 weeks or planned blood donation during the study&#xD;
&#xD;
          -  Subjects requiring regular transfusions for any reason&#xD;
&#xD;
          -  Subjects may also be excluded for any reason that may compromise their safety or the&#xD;
             accuracy of research data.&#xD;
&#xD;
          -  Subjects being treated with tamoxifen, estrogens, or progestins that have not been&#xD;
             stable for &gt;4 weeks.&#xD;
&#xD;
          -  Subjects that thyroid stimulating hormone (TSH) levels are greater than 1.5 x Upper&#xD;
             Limit of Normal (ULN) or clinical evidence of hypothyroidism&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcelo J Amar, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2015-H-0173.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <verification_date>July 24, 2019</verification_date>
  <study_first_submitted>July 31, 2015</study_first_submitted>
  <study_first_submitted_qc>July 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2015</study_first_posted>
  <results_first_submitted>September 28, 2020</results_first_submitted>
  <results_first_submitted_qc>November 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 3, 2020</results_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LDL-C</keyword>
  <keyword>Omega-3 Fatty Acid</keyword>
  <keyword>PCSK9</keyword>
  <keyword>HDL-C</keyword>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT02514070/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>44 participants enrolled on protocol. 5 of these 44 participants were considered screen failures. 39 participants started the protocol.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: EPA-rich Fish Oil Then DHA-rich Fish Oil</title>
          <description>Eicosapentaenoic acid (EPA)-rich fish oil 4 capsules 3 times per day after meal for a total of 3g per day for 6 weeks, followed by an 8-week washout period. Then docosahexaenoic acid (DHA)-rich fish oil 4 capsules 3 times per day after meal for a total of 3g per day for 6 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: DHA-rich Fish Oil Then EPA-rich Fish Oil</title>
          <description>Docosahexaenoic acid (DHA)-rich fish oil 4 capsules 3 times per day after meal for a total of 3g per day for 6 weeks, followed by an 8-week washout period. Then Eicosapentaenoic acid (EPA)-rich fish oil 4 capsules 3 times per day after meal for a total of 3g per day for 6 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Weeks 0 to Week 6</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Week 6 to Week 14 - Washout Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Week 14 to Week 20</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: EPA-rich Fish Oil, Then DHA-rich Fish Oil</title>
          <description>Eicosapentaenoic acid (EPA)-rich fish oil 4 capsules 3 times per day after meal for a total of 3g per day for 6 weeks, followed by an 8-week washout period. Then docosahexaenoic acid (DHA)-rich fish oil 4 capsules 3 times per day after meal for a total of 3g per day for 6 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: DHA-rich Fish Oil, Then EPA-rich Fish Oil</title>
          <description>Docosahexaenoic acid (DHA)-rich fish oil 4 capsules 3 times per day after meal for a total of 3g per day for 6 weeks, followed by an 8-week washout period. Then Eicosapentaenoic acid (EPA)-rich fish oil 4 capsules 3 times per day after meal for a total of 3g per day for 6 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31" spread="10.7"/>
                    <measurement group_id="B2" value="34" spread="11.2"/>
                    <measurement group_id="B3" value="32" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma PCSK9 Levels at Baseline and End of 6 Week Intervention</title>
        <description>Measure plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) level, at baseline, after 6 weeks of Eicosapentaenoic acid (EPA) or Docosahexaenoic acid (DHA) fish oil supplementation.</description>
        <time_frame>baseline to 6 weeks of intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>All study participants.</description>
          </group>
          <group group_id="O2">
            <title>EPA-rich Fish Oil</title>
            <description>Eicosapentaenoic acid (EPA)-rich fish oil 4 capsules 3 times per day after meal for a total of 3g per day for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>DHA-rich Fish Oil Arm</title>
            <description>Docosahexaenoic acid (DHA)-rich fish oil 4 capsules 3 times per day after meal for a total of 3g per day for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma PCSK9 Levels at Baseline and End of 6 Week Intervention</title>
          <description>Measure plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) level, at baseline, after 6 weeks of Eicosapentaenoic acid (EPA) or Docosahexaenoic acid (DHA) fish oil supplementation.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.30" spread="3.62"/>
                    <measurement group_id="O2" value="14.11" spread="4.36"/>
                    <measurement group_id="O3" value="12.44" spread="3.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Levels in Triglyceride, Cholesterol, and Lipoprotein From Baseline to 6 Weeks</title>
        <description>Measure plasma levels at baseline to 6 weeks of intervention for the following: triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), lipoprotein particle composition and size, and high-density lipoprotein (HDL) cholesterol efflux capacity.</description>
        <time_frame>Baseline to 6 weeks of intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>All study participants</description>
          </group>
          <group group_id="O2">
            <title>EPA-rich Fish Oil</title>
            <description>Eicosapentaenoic acid (EPA)-rich fish oil 4 capsules 3 times per day after meal for a total of 3g per day for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>DHA-rich Fish Oil</title>
            <description>Docosahexaenoic acid (DHA)-rich fish oil 4 capsules 3 times per day after meal for a total of 3g per day for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Levels in Triglyceride, Cholesterol, and Lipoprotein From Baseline to 6 Weeks</title>
          <description>Measure plasma levels at baseline to 6 weeks of intervention for the following: triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), lipoprotein particle composition and size, and high-density lipoprotein (HDL) cholesterol efflux capacity.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Triglyceride (TG)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.3" spread="66.6"/>
                    <measurement group_id="O2" value="81.7" spread="64.2"/>
                    <measurement group_id="O3" value="82.1" spread="57.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol (TC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190.9" spread="52.7"/>
                    <measurement group_id="O2" value="191.1" spread="49.5"/>
                    <measurement group_id="O3" value="193.5" spread="54.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.1" spread="49.6"/>
                    <measurement group_id="O2" value="111.4" spread="49.8"/>
                    <measurement group_id="O3" value="113.8" spread="52.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct LDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.7" spread="48.6"/>
                    <measurement group_id="O2" value="114.8" spread="51.3"/>
                    <measurement group_id="O3" value="120.6" spread="49.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small Dense LDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="19.9"/>
                    <measurement group_id="O2" value="37.3" spread="22.9"/>
                    <measurement group_id="O3" value="39.1" spread="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-TG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" spread="4"/>
                    <measurement group_id="O2" value="12.9" spread="4.3"/>
                    <measurement group_id="O3" value="12.8" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" spread="18.9"/>
                    <measurement group_id="O2" value="63.4" spread="20.2"/>
                    <measurement group_id="O3" value="63.4" spread="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct HDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.4" spread="16.8"/>
                    <measurement group_id="O2" value="60" spread="14.8"/>
                    <measurement group_id="O3" value="63.9" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoE-HDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="1.8"/>
                    <measurement group_id="O2" value="5.4" spread="1.6"/>
                    <measurement group_id="O3" value="5.9" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>20 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>EPA-rich Fish Oil</title>
          <description>Eicosapentaenoic acid (EPA)-rich fish oil 4 capsules 3 times per day after meal for a total of 3g per day for 6 weeks.</description>
        </group>
        <group group_id="E2">
          <title>DHA-rich Fish Oil</title>
          <description>Docosahexaenoic acid (DHA)-rich fish oil 4 capsules 3 times per day after meal for a total of 3g per day for 6 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Washout Period</title>
          <description>8 week washout period to occur between week 6 and week 14. No study supplement taken by subject at this time.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marcelo J. Amar, M.D. Principal Investigator, NIH, NHLBI</name_or_title>
      <organization>National Heart Lung and Blood Institute (NHLBI)</organization>
      <phone>301-402-0521</phone>
      <email>mamar@nhlbi.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

